CUSIP: G63637139
Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / SHS NEW 2022
-
Total 13F shares
-
95,811
-
Share change
-
+25,531
-
Total reported value
-
$181,549
-
Price per share
-
$1.89
-
Number of holders
-
11
-
Value change
-
+$47,184
-
Number of buys
-
7
-
Number of sells
-
1
Quarterly Holders Quick Answers
What is CUSIP G63637139?
CUSIP G63637139 identifies NBRVF - NABRIVA THERAPEUTICS PLC - SHS NEW 2022 in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q1 2023
-
Previous quarter:
Q3 2022
Recent filing periods for CUSIP G63637139:
Institutional Holders of NABRIVA THERAPEUTICS PLC - SHS NEW 2022 (NBRVF) as of Q4 2022
As of 31 Dec 2022,
NABRIVA THERAPEUTICS PLC - SHS NEW 2022 (NBRVF) was held by
11 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
95,811 shares.
The largest 10 holders included
Values First Advisors, Inc., RENAISSANCE TECHNOLOGIES LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Frazier Life Sciences Management, L.P., MORGAN STANLEY, ADVISOR GROUP HOLDINGS, INC., UBS Group AG, BANK OF AMERICA CORP /DE/, IFP Advisors, Inc, and Addison Advisors LLC.
This page lists
11
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.